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Abstract: In light of the recent outbreak of Ebola virus (EBOV) disease in West Africa, there have been
renewed efforts to search for effective antiviral countermeasures. A range of compounds currently
available with broad antimicrobial activity have been tested for activity against EBOV. Using live
EBOV, eighteen candidate compounds were screened for antiviral activity in vitro. The compounds
were selected on a rational basis because their mechanisms of action suggested that they had the
potential to disrupt EBOV entry, replication or exit from cells or because they had displayed some
antiviral activity against EBOV in previous tests. Nine compounds caused no reduction in viral
replication despite cells remaining healthy, so they were excluded from further analysis (zidovudine;
didanosine; stavudine; abacavir sulphate; entecavir; JB1a; Aimspro; celgosivir; and castanospermine).
A second screen of the remaining compounds and the feasibility of appropriateness for in vivo testing
removed six further compounds (ouabain; omeprazole; esomeprazole; Gleevec; D-LANA-14; and
Tasigna). The three most promising compounds (17-DMAG; BGB324; and NCK-8) were further
screened for in vivo activity in the guinea pig model of EBOV disease. Two of the compounds,
BGB324 and NCK-8, showed some effect against lethal infection in vivo at the concentrations tested,
which warrants further investigation. Further, these data add to the body of knowledge on the
antiviral activities of multiple compounds against EBOV and indicate that the scientific community
should invest more effort into the development of novel and specific antiviral compounds to treat
Ebola virus disease.
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1. Introduction
Ebolavirus is a genus of the family Filoviridae and includes five species: Bundibugyo virus
(BDBV), Reston virus (RESTV), Sudan virus (SUDV), Taï Forest virus (TAFV) and Ebola virus (EBOV).
Ebola virus is the prototype species [1,2] (formally designated Zaire ebolavirus) and was responsible
for the large outbreak of Ebola virus disease (EVD) in parts of West Africa first recognized in December
2013 [3]. EBOV is the most virulent species of the family with a case mortality of up to 90%, whereas
the Reston species is virtually non-pathogenic in humans [4]. In response to the outbreak in West Africa
and the threat of further outbreaks in the absence of approved and proven therapeutics or vaccines,
there has been increased international, political, humanitarian and scientific momentum to identify
treatment strategies. In this context, during the 2013/2014 EBOV outbreak, Public Health England
(PHE) was approached by several academic and commercial entities requesting rapid evaluation of
repurposed drugs and experimental therapies for EBOV, using its Containment Level 4 (CL4) facilities.
With support from the Ebola research funding initiative from the Wellcome Trust, a project to determine
the viable drug candidates for further development was developed. The eighteen candidates in this
report were selected from sixty credible leads by a scientific panel; they covered a range of potentially
promising mechanisms of action against EBOV. Brief details of the compounds nominated for inclusion
are outlined below:
• Ouabain: Originally used for the treatment of heart diseases [5], which has been demonstrated to
reduce EBOV replication by around half when testing in vitro in a study looking into the viral
protein 24 (VP24) protein and the interruption of cellular interacting proteins [6]
• 17-DMAG: An inhibitor of heat shock protein 90 (HSP90), which has been shown to reduce
in vitro EBOV replication [7]
• BGB324: An inhibitor of Axl receptor tyrosine kinase, which appears to be involved with Ebola
virus entry into host cells [8]
• JB1a: An antibody therapy, targeting beta-1 integrins, which have been proposed to facilitate
the entry of filoviruses; treatment of target cells with the JB1a clone reduced infection using a
vesicular stomatitis virus (VSIV) pseudotyped with EBOV glycoprotein [9]
• Omeprazole and esomeprazole magnesium: Members of the benzimidazoles that may stop viral
entry via clathrin-mediated endocytosis by raising the endosomal pH. Both compounds were
shown to inhibit lentivirus-based pseudotypes expressing EBOV glycoprotein [10]
• Gleevec and Tasigna (market names for imatinib mesylate and nilotinib, respectively): Specific
tyrosine kinase inhibitors originally developed as anticancer compounds and proposed to inhibit
phosphorylation of the VP40 matrix protein which is required for EBOV exit from cells [11].
During large-scale screens of antivirals against EBOV, other groups have identified Gleevec [12]
and Tasigna [13] as potential EBOV inhibitors
• Aimspro (anti-inflammatory immuno-suppressive drug): Originally developed for the treatment
of human immunodeficiency virus (HIV) by the production of hyperimmune serum in goats
injected with inactivated HIV IIIB, the serum has revealed the presence of a range of components,
including the cytokines interleukin (IL)-4 and IL-10, proopiomelanocortin, arginine vasopressin,
β-endorphin and corticotropin-releasing factor [14]
• NCK-8 and D-LANA-14: Small molecules that mimic the properties of antimicrobial peptides,
NCK-8 [15,16] and D-LANA-14 [17] have demonstrated potent activity against drug-resistant
bacteria and their biofilms. The activity of this class of compounds is attributed to their membrane
disrupting properties [18–20]. Peptide mimics [21] and several other small molecules have
demonstrated activity against EBOV. Owing to the membrane-disrupting [22,23] modes of action
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of this class of compounds (e.g., NCK-8 and DLANA-14), they were expected to be active
against EBOV
• Celgosivir and its prodrug castanospermine: Broad spectrum inhibitors of host glucosidases.
Inhibitors of endoplasmic reticulum (ER) α-glucosidases have been shown to act as antivirals
with several haemorrhagic fever viruses, including EBOV [24]
• Zidovudine, didanosine, stavudine, abacavir sulphate and entecavir: Compounds included in the
study upon request of the Wellcome Trust
2. Materials and Methods
2.1. In Vitro Screening
2.1.1. Virus Assay
MRC-5 (human foetal lung) and VeroE6 (African Green monkey kidney) cells were sourced from
the European Collection of Cell Cultures (ECACC) and seeded into 96-well plates. MRC-5 cells were
chosen as a host-matched human cell line susceptible to EBOV infection [6] and VeroE6 for being
widely used in EBOV studies [25–27]. Compounds were sourced commercially (Selleck Chemicals,
Boston, MA, USA; and Dalton Pharm Services, Toronto, ON, Canada) wherever possible or directly
from the supplier if they were not readily available (BGB324, BerGenBio, Bergen, Norway; JB1a,
Avipero, Edinburgh, UK; Aimspro, Daval International, Eastbourne, UK). NCK-8 and D-LANA-14
were synthesized and characterized in Jawaharlal Nehru Centre for Advanced Scientific Research, India.
Stock solutions of these compounds were made at double the final dilution to take into account an equal
volume of virus suspension to be added. Several stocks were supplied in dimethyl sulfoxide (DMSO)
solution. After dilution, the highest concentration of DMSO was ≤0.05%, except for omeprazole and
esomeprazole, where the highest concentrations were 10% and 7.5%, respectively.
Within the CL4 laboratory, media were removed from the inner wells of 96-well plates. Due to
edge-effects, the outer wells were left with media added. Compounds were added at five replicates
per dilution; three for virus addition and two mock-infected. For the first in vitro screen, EBOV
suspension (strain ME718, recently renamed 1976/Yambuku-Ecran [28]) was added at a TCID50 (tissue
culture infectious dose 50 percent) concentration of approximately 500/well to triplicate wells per
compound dilution, with the remaining two wells having media alone added. Based on the inhibition
of EBOV-induced cytopathic effect in different cell lines, the supernatants from MRC-5 and VeroE6
cells were harvested on days 3 and 6 post-infection, respectively. Cells were microscopically assessed
for the condition of the monolayer.
2.1.2. Molecular Assay
Viral replication was measured and compared over a series of time points using a real-time
polymerase chain reaction (PCR) approach. One hundred forty microliters of supernatant were added
to 560 µL AVL buffer for RNA extraction in sealable deep 96-well plates for removal from the CL4
laboratory. Extraction of RNA was performed using the MagnaPure 96 small volume RNA kit (Roche,
Burgess Hill, UK), a magnetic bead-based method of RNA separation. In brief, samples were vessel
transferred into MagnaPure plates prior to loading onto the MagnaPure 96 automated extraction robot
and RNA eluted in 60 µL nuclease-free water. Target amplification was performed using primers to
Zaire ebolavirus glycoprotein as described in Trombley et al., [29] using the Fast Virus qRT-PCR Kit
(Qiagen, Manchester, UK). Analysis was performed using the ABi 7500 (Applied Biosystems, Paisley,
UK) under the following cycling conditions: 50 ◦C for 10 min, 95 ◦C for 30 s followed by 40 cycles of
95 ◦C for 15 s and 60 ◦C for 3 s; temperature cycling was set to the maximum ramp speed, and data
were acquired and analyzed using the ABi 7500 on-board software version 2.0.6 (Applied Biosystems,
Paisley, UK) with a threshold set to 0.05. Cycle threshold (Ct) values from the PCR assay were used to
give a consistent reading of the amount of EBOV RNA levels in the samples.
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2.1.3. Toxicity Assay
Six compounds of interest were assessed for toxicity, based on availability and results from the first
in vitro screening and availability (i.e., omeprazole, esomeprazole, ouabain, 17-DMAG, Gleevec and
BGB324). Serial dilutions were made and incubated on MRC-5 cells for three days. After incubation,
cells were visually assessed for cytotoxicity, and monolayers were fixed with formaldehyde solution
before staining with crystal violet for a gross visual inspection of cell attachment.
2.1.4. Repeat Compound Screening
Screening assays were repeated to assess for effects against EBOV using MRC-5 cells.
The following changes to the previous method were employed: (i) compounds were tested in dilutions
shown not to exert a cytotoxic effect on uninfected MRC-5 cells; (ii) a 10× higher viral inoculum was
used (approximately 5000 TCID50/well); and (iii) samples were harvested after two days.
2.2. In Vivo Screening
Guinea pigs were used for efficacy studies [30] using group sizes of n = 6. Animal studies were
performed under CL4 conditions with all procedures being undertaken according to the United
Kingdom Animals (Scientific Procedures) Act 1986. Studies were approved by the PHE ethics
committee and the Project Licence approved by a UK Home Office inspector. Vascular catheters
were inserted prior to arrival to allow safe access to the intravenous route of delivery at CL4. Animals
were challenged via the subcutaneous route with a dose of 103 TCID50 guinea pig-adapted EBOV
that had been passaged five times in vivo [31]. The challenge preparation was back titrated in VeroE6
cells to confirm the dose. At 6 h post-challenge, treatment was initiated with the compounds BGB324,
NCK-8 and 17-DMAG. BGB324 was dissolved in 0.5% (w/w) hydroxypropyl methylcellulose/0.1%
(w/w) Tween-80 to give a concentration that equated to 100 mg/kg in 1 mL. Doses of 1 mL were
given orally twice daily. Compound NCK-8 was diluted with sterile water to give a concentration
that equated to 5 mg/kg. One milliliter was delivered via the intravenous (i.v.) route twice daily.
17-DMAG was supplied commercially (Selleck, product S1142) and dissolved in 0.05% DMSO to
give a concentration that equated to 30 mg/kg in 1 mL. Doses were delivered intraperitoneally (i.p.)
and scheduled for every other day. A negative control group consisted of guinea pigs that were
EBOV challenged, but received no treatment. Each day, animals were individually weighed and their
temperatures were recorded by a subcutaneously-inserted temperature/identification (ID) chip.
To prevent unnecessary animal suffering, humane clinical endpoints were used, which
standardized when animals would be culled using a UK Home Office approved Schedule 1 method.
The endpoints consisted of: (a) 10% weight loss and a moderate clinical symptom (e.g., lethargy, etc.);
(b) 20% weight loss; or (c) showing signs of distress, as determined in consultation with the named
Animal Care and Welfare Officer.
3. Results
3.1. Selection of Compounds
Due to the large number of compounds (about sixty) initially proposed for antiviral testing,
a scoring assessment was undertaken to triage compounds in relation to the capacity available for
testing at CL4. The assessment was based on Technical Readiness Level (TRL) (Table A1, adapted from
United States Department of Defense, 2009 [32]), availability and previous evidence of efficacy against
EBOV (Table A2). In addition, companies and institutions who had suggested the compounds were
asked to score their drugs themselves and to provide justifications. With this information, together
with information from the publicly-available literature at the time, a scientific panel identified eighteen
compounds that were suitable for screening (Table 1).
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Table 1. Scoring of selected compounds for Ebola virus (EBOV) screening. TRL, Technical Readiness Level.
Name TRL Score 1 Availability 2 Efficacy 3 Total
Ouabain 4 2 1 7
17-DMAG 4 2 1 7
BGB324 4 2 1 7
Zidovudine 4 2 1 7
Didanosine 4 2 1 7
Stavudine 4 2 1 7
Abacavir sulphate 4 2 1 7
Entecavir 4 2 1 7
JB1a 3 2 1 6
Omeprazole 3 2 1 6
Esomeprazole magnesium 3 2 1 6
Gleevec 3 2 0.5 5.5
Aimspro 3 2 0 5
NCK-8 3 2 0 5
D-LANA-14 3 2 0 5
Tasigna 3 1 0.5 4.5
Celgosivir 2 2 0 4
Castanospermine 2 2 0 4
1 Scored from 1 to 9 (TLR table; Appendix A). 2 Availability for use in the clinic. 3 Previous data on efficacy
against EBOV.
3.2. Effects of Compounds against In Vitro EBOV Replication
3.2.1. Initial Screen at Recommended Concentration
The recommended use concentration for each compound was sought from the suppliers and/or
information in the public domain. Using these concentrations, the levels of EBOV RNA after infection
of two cell lines, MRC-5 and VeroE6, were assessed to give a readout of viral replication. In addition to
viral RNA levels, the cytopathic effects (CPEs) were assessed for toxic effects (Table 2). Results identified
nine compounds that had no reduction in viral replication despite cells remaining healthy, and
these (zidovudine, didanosine, stavudine, abacavir sulphate, entecavir, JB1a, Aimspro, celgosivir,
and castanospermine) were removed from further evaluation. While several compounds showed a
reduction in viral RNA levels, these drugs (ouabain, 17-DMAG, omeprazole, esomeprazole magnesium,
Gleevec, and Tasigna) also exhibited significant CPE in cell monolayers. However, three compounds
gave reductions in the Ct value with cells remaining attached: BGB324, NCK-8 and D-LANA-14; albeit
that the latter two compounds did affect the morphology of the cells to some extent.
Table 2. Changes in EBOV RNA levels and cell health in MRC-5 and VeroE6 cells treated after infection
with compounds at the recommended concentrations.
Name Concentration
MRC-5 VeroE6
Ct Difference 1 Cell Appearance 2 Ct Difference Cell Appearance
Ouabain 20 nM 3.48 ± 0.21 x −3.73 ± 4.88 x
17-DMAG 5 µM 3.72 ± 0.18 x −0.63 ± 1.39 x
BGB324 3 µM 3.05 ± 0.75 3 −1.83 ± 1.13 3
Zidovudine 5 µM −3.12 ± 0.27 3 −7.91 ± 2.67 3
Didanosine 5 µM −0.43 ± 3.87 3 −2.52 ± 1.27 3
Stavudine 5 µM −2.87 ± 0.22 3 −3.93 ± 0.25 3
Abacavir sulphate 5 µM −1.54 ± 3.26 3 −3.95 ± 2.69 3
Entecavir 5 µM −3.08 ± 0.20 3 −4.44 ± 1.11 3
JB1a 2 µg/mL −4.02 ± 0.13 3 −5.48 ± 0.50 3
Omeprazole 100 µM 1.35 ± 1.35 x 2.21 ± 1.08 x
Esomeprazole
magnesium 75 µM 1.05 ± 0.79 x 1.62 ± 0.36 x
Gleevec 20 µM 3.60 ± 0.63 x 3.49 ± 0.54 x
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Table 2. Cont.
Name Concentration
MRC-5 VeroE6
Ct Difference 1 Cell Appearance 2 Ct Difference Cell Appearance
Aimspro Neat −2.03 ± 0.95 3 −4.60 ± 1.15 3
NCK-8 1 mg/mL >10 * >10 *
D-LANA-14 1 mg/mL >10 * >10 *
Tasigna 20 µM 3.59 ± 0.57 x −0.13 ± 0.33 3
Celgosivir 200 µM −2.52 ± 0.21 3 −2.41 ± 0.12 3
Castanospermine 200 µM −1.58 ± 3.23 3 −0.26 ± 4.11 3
1 Difference between mean value of untreated cells (n = 3) versus treated cells (n = 3). A positive value indicates a
reduction in viral RNA levels. Values shown are mean of triplicates ± standard deviation. 2 Presence of healthy
and adherent cells. Asterisks indicate that cells were attached, but with a changed morphological appearance.
3.2.2. Secondary Screening with a High Virus Inoculation
A repeat screening assay of compounds that showed anti-EBOV activity was conducted using
MRC-5 cells only, as in the initial screen, similar responses were observed between MRC-5 and VeroE6
cells, with a higher concentration of virus inoculum and incubation for two days. Additionally, for
the compounds that were previously tested at the recommended concentration, but had exerted a
cytotoxic effect, the concentrations used were adjusted to determine the optimum concentration that
caused tolerable toxicity after incubation on uninfected MRC-5 cells for two days. Results from this
experiment confirmed the in vitro antiviral activity against EBOV for all compounds tested (Table 3).
Table 3. Changes in EBOV RNA levels in MRC-5 cells treated with compounds at three dilutions
determined not to cause cytotoxicity in non-infected treated cells.
Name Concentration Ct Difference 1
Ouabain
20 nM 0.06 ± 0.10
6.7 nM 0.09 ± 0.23
2.2 nM 0.33 ± 0.35
17-DMAG
63.3 nM 0.30 ± 0.20
21.1 nM 0.26 ± 0.57
7.0 nM 0.44 ± 0.06
BGB324
1 µM 0.90 ± 0.15
0.3 µM 0.67 ± 0.09
0.1 µM 0.34 ± 0.05
Omeprazole
100 µM 0.70 ± 0.10
33.3 µM 0.77 ± 0.31
11.1 µM 0.86 ± 0.22
Esomeprazole
25 µM 0.78 ± 0.25
8.3 µM 0.50 ± 1.06
0.93 µM 0.17 ± 0.16
Gleevec
6.7 µM 1.55 ± 0.20
2.2 µM 1.03 ± 0.42
0.74 µM 0.64 ± 0.03
NCK-8
150 µg/mL 1.54 ± 0.44
50 µg/mL 1.33 ± 0.09
16.7 µg/mL 1.09 ± 0.17
D-LANA-14
60 µg/mL 0.96 ± 0.19
20 µg/mL 0.37 ± 0.11
6.7 µg/mL 0.40 ± 0.32
1 Difference between the mean value of untreated cells (n = 3) versus treated cells (n = 3). A positive value
indicates a reduction in viral RNA levels. Values shown are the mean of triplicates ± standard deviation.
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3.3. Screening of Compounds for Effects against Disease in EBOV-Infected Guinea Pigs
Three of the compounds that had demonstrated in vitro activity against EBOV were screened
for effects against EBOV disease in the guinea pig model: 17-DMAG, BGB324, and NCK-8.
These compounds were chosen because they had caused the highest levels of viral RNA reduction,
represented different modes of activities and were suitable for use in the current in vivo model without
further modification or changes to ethical licensing.
3.3.1. Testing of BGB324 in EBOV-Infected Guinea Pigs
BGB324 was delivered orally with two doses per day starting at 6 h post-challenge. Results showed
that BGB324 treatment failed to exert any statistically-significant protective effects compared to
untreated animals (n = 6 per group; p = 0.358, log-rank survival analysis) (Figure 1a). Weight and
temperature differences post-EBOV challenge showed that animals that met humane clinical endpoints
exhibited weight loss and all animals had a rise in temperature (Figure 1b,c). However, weight
loss was not observed in one animal from the BGB324-treated group, which survived until day 18
post-challenge, the scheduled end of the study. This indicates that in this animal, BGB324 exerted a
protective effect.
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Figure 1. Survival and clinical parameters of guinea pigs treated with 100 mg/kg BGB324 twice daily
compared to untreated controls (n = 6 per group). (a) Survival analysis after challenge with 103 TCID50
EBOV; (b) Weight changes as a percentage compared to the day of challenge; (c) Temperature changes
as ◦C difference compared to the day of challenge.
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3.3.2. Testing of NCK-8 in EBOV-Infected Guinea Pigs
NCK-8 was delivered intravenously with two doses per day starting at 6 h post-challenge.
Although an increase in time to death was observed, this was not statistically significant (n = 6 per
group; p = 0.076, log-rank survival analysis) (Figure 2a). All animals exhibited weight loss and had a
rise in temperature (Figure 2b,c). An animal in the NCK-8-treated group began to increase its weight
nine days post-challenge, indicating a recovery from EBOV infection. This animal survived to the
scheduled end of the study.Viruses 2016, 8, 277  8 of 18 
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we developed an experimental workflow to rapidly screen compounds for antiviral activity in order
to focus efforts and resources on only the most promising therapies. In the first in vitro screen using
500 TCID50/well (multiplicity of infection (MOI) approximately 0.01), half of the compounds failed to
show any activity, so these compounds were excluded from further study. For a second screen using
5000 TCID50/well (MOI approximately 0.1), eight of the remaining nine compounds continued to
demonstrate a mean reduction in viral replication. In this screen, the drug Tasigna was not retested
due to compound unavailability, but additionally, the drug Gleevec was included since it was reported
to operate via the same mechanism and demonstrated better in vitro efficacy. The in vitro screens
used viral RNA levels as a readout based on previous antiviral testing work [33] and infectious doses
of MOI 0.01–0.1, similar to levels used in other anti-EBOV testing studies [6,34,35]. Given that the
compounds tested in our study were chosen due to their perceived potential effectiveness for use
against EBOV, the negative results demonstrate the importance of testing therapies using the actual
live pathogen to determine effects. They also highlight the uncertainties inherent in extrapolating the
mechanism of action data to drug repurposing, no matter how rational.
Of the eight compounds that showed repeatable antiviral activity against EBOV in vitro, three
were selected for in vivo studies using the guinea pig model of infection (i.e., 17-DMAG, BGB324
and NCK-8). Whereas omeprazole and esomeprazole demonstrated in vitro activity against EBOV,
the results were in line with a previous report using pseudotyped viruses where the values of drug
concentration causing 50% inhibition (IC50) were in the region of 50 µM [10]. This suggested that
doses required for potent inhibition would be difficult to achieve without concomitant and significant
toxicity (the licenced dosing for 40 mg esomeprazole, 20 mg esomeprazole and 20 mg omeprazole
generates median maximum plasma concentrations of 1.59–9.61 µM, 0.51–4.78 µM and 0.15–3.51 µM,
respectively [36]). Gleevec (brand name for imatinib mesylate) was not followed through for in vivo
testing since the optimal dosing requirement (i.e., continuous dosing) was not feasible for the current
set-up of the animal model at CL4. The requirement for continuous dosing is due to the short half-life
in rats of a similar compound [37]. Additionally, the plasma concentrations of Gleevec usually reach
2–3 µM at normal dosages [38]. Others have suggested that the concentration for effective EBOV
inhibition is 20 µM [11], which would not be possible. However, the data from the in vitro studies
with live EBOV reported here show effects even when 0.74 µM was used. NCK-8 and D-LANA-14 are
membrane-active small molecules that mimic the properties of natural antimicrobial peptides and may
negatively impact the viral envelope and cellular lipid bilayer. Out of the two molecules, D-LANA-14,
was less active; hence its efficacy was not assessed in the animal model. The guinea pig model of EBOV
disease was used in this work since it presents a robust, accessible and broadly reflective rodent model
for the screening of countermeasures [39]. Importantly, the model also allows catheterized animals
to be used, allowing direct access to the intravenous route. This is the preferred route of delivery for
many antiviral compounds and is compatible for work at the highest microbiological containment [30].
No positive effects of BGB324 against EBOV infection in guinea pigs were observed in relation to
survival. Both BGB324-treated and untreated controls exhibited 83% mortality. However, the survivor
in the BGB324-treated group did not show the significant loss in weight that is typical of EBOV-infected
guinea pigs [31] and that was exhibited by the survivor in the untreated group. Both surviving guinea
pigs exhibited an increase in temperature typical of EBOV infection in this model [31]. It is possible
that these observations are a consequence of broad guinea pig responses, since these animals were
outbred individuals and there were subtle differences between their responses. The effects of BGB324
were proposed to be due to the inhibition of tyrosine kinase inhibitors [40]. Thus, it could be speculated
that other tyrosine kinase inhibitors, including the two in this study (Gleevec and Tasigna), would also
not have demonstrated protective effects.
Treatment of EBOV-challenged guinea pigs with NCK-8 was the only instance that showed an
effect on disease progression, with a demonstrable increased mean time to death; albeit, this was
not statistically significant. All animals treated with NCK-8 exhibited weight loss and temperature
increases, in line with the levels of untreated animals. Interestingly, this class of compounds has been
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tested against bacterial pathogens [15,19,41] and has been found to be quite effective. Other peptide
mimics have demonstrated antiviral activity against EBOV, as well [21]. However, it should be noted
that although NCK-8 showed high levels of antiviral activity, the cell monolayers were phenotypically
different for both VeroE6 and MRC-5 cell lines. This observation warrants further investigation,
especially the dependence of activity on the concentration of the compounds. Nevertheless, NCK-8 was
well-tolerated when tested in guinea pigs and led to the recovery of one animal from EBOV infection.
When tested in guinea pigs, the effects of 17-DMAG could not be clearly ascertained since these
animals met humane endpoints prior to disease symptoms of EBOV disease. The dose used in our
study was 30 mg/kg; whereas there are no reports of 17-DMAG being used in guinea pigs, others have
shown that 75 mg/kg delivered orally was well tolerated in mice and rats [42]. Therefore, it is likely
that there is a non-compatible interaction with a component of guinea pig physiology that results in
a toxic effect. To further test the effectiveness of 17-DMAG against EBOV, an animal system where
the compound has shown to be non-toxic should be used, such as the mouse. However, due to the
mouse model not being as relevant to human disease as the guinea pig [43], the value of conducting
such studies may be counterproductive.
In summary, our results provide details on the antiviral properties of eighteen potential therapies.
Whereas the experiments were limited and could have been extended to include viable viral loads by
plaque assay or modern methods for the assessment of cytotoxicity, the studies were conducted to
provide rapid results during an active EBOV outbreak and within the limitations of CL4 facilities where
all handling of live EBOV was within a specialized cabinet-line system. Candidates for this study were
chosen via a project-specific selection committee (comprising of members from PHE, academia and
the Wellcome Trust), not by screening approaches of a large number of compounds [12,44,45], so were
more selective based on perceived activity against EBOV. However, the value of this work is the use
of live EBOV, providing valuable insight into compounds that warrant further investigation and, as
important, those that showed no antiviral effects against EBOV.
5. Conclusions
In conclusion, the data in this report will help to inform decisions on which compounds should
be investigated further and, equally importantly, which ones should not. Given the limited facilities
and restrictions of working with live Hazard Group 4 viruses, the focus should now be on treatments
that have shown promise with live EBOV using in vitro and in vivo models.
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Appendix A
Table A1. Technical Readiness Level (TRL) scoring.
U.S. Army Medical Research and Material Command (USAMRMC) equivalent TRL descriptions for drugs, biologics and vaccines (pharmaceuticals) synthesized from the Technology
Readiness Assessment (TRA) Deskbook [46].
TRL Description Decision Criterion Supporting Information
1
Lowest level of technology readiness. Maintenance of
scientific awareness and generation of scientific and
bioengineering knowledge base. Scientific findings are
reviewed and assessed as a foundation for characterizing
new technologies.
Scientific literature reviews and initial market
surveys are initiated and assessed. Potential
scientific application to defined problems
is articulated.
Reviews of open, published scientific literature concerning
basic principles. Findings from market surveys of the open
literature. Privately funded research findings or market
surveys are proprietary and rarely available to the public
but could be made available upon request under
confidentiality agreement.
2
Intense intellectual focus on the problem, with generation
of scientific “paper studies” that review and generate
research ideas, hypotheses, and experimental designs for
addressing the related scientific issues.
Hypothesis(es) is (are) generated. Research plans
and/or protocols are developed, peer reviewed,
and approved.
Focused literature reviews are conducted and scientific
discussions are held to generate research plans and studies
that identify potential targets of opportunity for therapeutic
intervention and to facilitate strategic planning. Supporting
analyses provide scientific information and data for
developing research proposals for filling in data gaps and
identifying candidate concepts and/or therapeutic drugs.
Documented by peer-reviewed approved protocol(s) or
research plan(s).
3
Basic research, data collection, and analysis begin in order
to test hypothesis, explore alternative concepts, and
identify and evaluate critical technologies and components
supporting research and eventual development of the
pharmaceutical candidate, identification of sites and
mechanisms of action (and potential correlates of protection
for vaccines), as well as initial characterization
of candidates.
Initial proof-of-concept for candidate constructs is
demonstrated in a limited number of in vitro and
in vivo research models.
Documentation of the results of laboratory studies
demonstrates preliminary proof-of-concept (with candidate
constructs) from in vitro and animal studies.
4
Non- good laboratory practice (GLP) research to refine
hypothesis and identify relevant parametric data required
for technological assessment in a rigorous (worst case)
experimental design. Exploratory study of candidate drugs
or of critical technologies for effective integration into
candidate biologic/vaccine constructs. Candidate drugs (or
biologics/vaccines) are evaluated in animal model(s) to
identify and assess safety, toxicity and
adverse/biological/side effects, and assays (and/or
surrogate markers and endpoints) to be used during
non-clinical and clinical studies to evaluate and
characterize candidate pharmaceuticals are identified.
Proof-of-concept and safety of candidate drug
formulations (or candidate biologic/vaccine
constructs) are demonstrated in defined
laboratory/animal model(s).
Documented proof-of-concept and safety of the candidate
are demonstrated by results of formulation studies (or
proposed production/purification methods of the
biologic/vaccine), laboratory tests, pharmacokinetic
studies, and selection of laboratory/animal models.
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Table A1. Cont.
TRL Description Decision Criterion Supporting Information
5
Intense period of non-clinical and preclinical research
studies involving parametric data collection and analysis in
well-defined systems, with pilot lots of candidate
pharmaceuticals produced and further development of
selected candidate(s). In the case of drug, results of research
with pilot lots provide basis for a manufacturing process
amenable to current good manufacturing practice
(cGMP)-compliant pilot lot production. In the case of
biologic/vaccine, research results support proposing a
potency assay, proposing a manufacturing process
amenable to cGMP-compliant pilot lot production,
identifying and demonstrating proof-of-concept for a
surrogate efficacy marker in an animal model(s) applicable
to predicting protective immunity in humans, and
demonstrating preliminary safety and efficacy against an
appropriate route of challenge in a relevant animal model.
Conduct GLP safety and toxicity studies in animal model
systems. Identify endpoints of clinical efficacy or its
surrogate. Conduct studies to evaluate pharmacokinetics
(PK) and pharmacodynamics (PD) and/or immunogenicity
as appropriate. Stability studies initiated.
A decision point is reached at which it is
determined that sufficient data on the candidate
pharmaceutical exist in the draft technical data
package to justify proceeding with preparation of
an investigational new drug (IND) application.
Reviewers confirm adequacy of information and data in
draft technical data package to support preparation of an
IND application. Documentation in the draft technical data
package contains data from animal pharmacology and
toxicology studies, proposed manufacturing information,
and clinical protocols suitable for phase 1 clinical testing.
6
Pre-IND meeting (type B) held and IND application
prepared and submitted to the Center for Drug Evaluation
and Research (CDER) or the Center for Biologics Evaluation
and Research (CBER). Phase 1 clinical trials are conducted
to demonstrate safety of candidate in a small number of
subjects under carefully controlled and intensely monitored
clinical conditions. Evaluation of PK and PD (and/or
immunogenicity) data to support the design of
well-controlled, scientifically valid phase 2 studies.
Production technologies for drug candidates are
demonstrated through production-scale cGMP plant
qualification, and surrogate efficacy models for
biologics/vaccines are validated.
Data from phase 1 clinical trials meet clinical
safety requirements and support proceeding to
phase 2 clinical trials.
For phase 1 clinical trials to begin, the following are needed:
the Food and Drug Administration (FDA)’s and sponsor’s
summary minutes of pre-IND meeting document
agreements and general adequacy of information and data
to support submission of IND application. Review of the
submitted IND application does not result in a FDA
decision to put a clinical hold on phase 1 clinical trials with
the candidate pharmaceutical. For entry into phase 2
clinical trials, the results from phase 1 clinical studies have
to demonstrate safety of candidate pharmaceutical. An
updated IND, amended with a new clinical protocol to
support phase 2 clinical trials or surrogate test plan and
submitted to the FDA, documents achieving this criterion.
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Table A1. Cont.
TRL Description Decision Criterion Supporting Information
7
Phase 2 clinical trials are conducted to determine
activity/efficacy/immunogenicity/safety/toxicity of the
pharmaceutical as appropriate. These and/or PK-PD data
are used to establish product final dose, dose range,
schedule, and route of administration. Data are collected,
presented and discussed at pre-phase 3 (or surrogate
efficacy] meeting (type B) with CDER (or CBER) in support
of continued drug development of the drug (or
biologic/vaccine), and clinical endpoints and/or surrogate
efficacy markers and test plans agreed.
Phase 3 clinical study plan or surrogate test plan
has been approved.
FDA’s summary minutes of pre-phase 3 meeting with
sponsor discussing results of phase 1 and phase 2 trials, as
well as protocols or test plans, provide a record of
agreements and basis for sponsor to proceed with phase 3
clinical study or surrogate test plan. An updated IND
application, amended with a new clinical protocol to
support phase 3 clinical trials or surrogate test plan and
submitted to the FDA, documents achieving this criterion.
8
Implementation of expanded phase 3 clinical trials or
surrogate tests to gather information relative to the safety
and effectiveness of the candidate drug/biologic/vaccine.
Trials are conducted to evaluate the overall risk–benefit of
administering the candidate product and to provide an
adequate basis for labelling. Process validation is
completed and followed by lot consistency/reproducibility
studies. In the case of a drug, New Drug Application
(NDA) is submitted to CDER following pre-NDA meeting
(type B). In the case of a biologic/vaccine, Biologics License
Application (BLA) is prepared and submitted to CBER
following pre-BLA meeting (type B). Facility Preapproval
Inspection (PAI) is completed.
Approval of the NDA for drug by CDER, or
approval of the BLA for biologics/vaccines
by CBER.
FDA issuance of an approval letter after their review of the
NDA or BLA application submitted by the sponsor for the
pharmaceutical documents this criterion.
9
The pharmaceutical (i.e., drug/biologic/vaccine) can be
distributed/marketed. Post-marketing studies (non-clinical
or clinical) may be required and are designed after
agreement with the FDA. Post-marketing surveillance.
None. Continue surveillance.
FDA transmits any requirement for post-marketing studies.
Begin post-approval reporting requirements. Maintain
cGMP compliance.
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Table A2. Additional Scoring Criteria
Points Description Decision Criteria Supporting Info
0 or 1 or 2
Availability to make a
difference to the
current epidemic
Repurposed pharmaceutical or the ability to
generate and supply sufficient material within
two weeks for in vitro and in vivo studies,
and if required subsequently, a reasonable
number of therapeutic doses to make a
difference to the current Public Health
Emergency of International Concern declared
by the World Health Organization (WHO).
Documentation to prove that the candidate is:
• a pharmaceutical licensed in a well-regulated (e.g., FDA, Medicines and
Healthcare products Regulatory Agency (MHRA)) market that does not
require further development and is widely available (score of 2); or
• used or approved for use in clinical trials or patients (e.g., under
Emergency Use Authorization or Expanded Access/ Compassionate
Use) with guaranteed availability (score of 2); or
• to be supplied as outlined in the decision criterion, with reliable
estimates on the feasibility, costs, timeline, etc. (score of 1).
Thus, the level/quality of existing data package, any licensure/indications in
humans, commitment/track record of the developers, and the feasibility to
supply sufficient doses for the study and subsequently to solve the current
epidemic should be well-documented.
0 or 0.5 or 1 or 2
Likely efficacy against the
pathogenic microorganism
of interest.
Prior efficacy data against the pathogenic
microorganism (or a related agent) of interest,
for example through reduction of load or
host-immune response.
Scientific studies, reports, commercial-in-confidence information
documenting evidence (e.g., theoretical or in silico, in vitro and/or in vivo
data) that the candidate is likely to be efficacious against the pathogenic
microorganism (or a related agent) of interest. Suggested score: in silico (0.5);
in vitro (1); in vivo (2)
0 or 1 or 2 Practicality andcost-effectiveness (tie-breaker)
Is it a practical and cost-effective solution for
frontline clinical response to the current, as
well as future epidemics?
Documentation to prove that:
• the current or likely formulation will not be complex (e.g., oral,
intravenous (i.v), multiple dosing), and any transition from the existing
gold standard treatment(s) would not be too difficult; and
• the candidate would or could be a cost-effective solution, especially to
make a difference to patients affected the current epidemic.
Viruses 2016, 8, 277 15 of 17
References
1. Adams, M.J.; Carstens, E.B. Ratification vote on taxonomic proposals to the International Committee on
Taxonomy of Viruses (2012). Arch. Virol. 2012, 157, 1411–1422. [CrossRef] [PubMed]
2. Kuhn, J.H.; Becker, S.; Ebihara, H.; Geisbert, T.W.; Johnson, K.M.; Kawaoka, Y.; Lipkin, W.I.; Negredo, A.I.;
Netesov, S.V.; Nichol, S.T.; et al. Proposal for a revised taxonomy of the family Filoviridae: classification,
names of taxa and viruses, and virus abbreviations. Arch. Virol. 2010, 155, 2083–2103. [CrossRef] [PubMed]
3. Baize, S.; Pannetier, D.; Oestereich, L.; Rieger, T.; Koivogui, L.; Magassouba, N.; Soropogui, B.; Sow, M.S.;
Keita, S.; De Clerck, H.; et al. Emergence of Zaire Ebola virus disease in Guinea. N. Engl. J. Med. 2014, 371,
1418–1425. [CrossRef] [PubMed]
4. Mahanty, S.; Bray, M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect. Dis. 2004, 4, 487–498.
[CrossRef]
5. Fuerstenwerth, H. On the differences between ouabain and digitalis glycosides. Am. J. Ther. 2014, 21, 35–42.
[CrossRef] [PubMed]
6. Garcia-Dorival, I.; Wu, W.; Dowall, S.; Armstrong, S.; Touzelet, O.; Wastling, J.; Barr, J.N.; Matthews, D.;
Carroll, M.; Hewson, R.; et al. Elucidation of the Ebola virus VP24 cellular interactome and disruption of
virus biology through targeted inhibition of host-cell protein function. J. Proteome Res. 2014, 13, 5120–5135.
[CrossRef] [PubMed]
7. Smith, D.R.; McCarthy, S.; Chrovian, A.; Olinger, G.; Stossel, A.; Geisbert, T.W.; Hensley, L.E.; Connor, J.H.
Inhibition of heat-shock protein 90 reduces Ebola virus replication. Antivir. Res. 2010, 87, 187–194. [CrossRef]
[PubMed]
8. Shimojima, M.; Ikeda, Y.; Kawaoka, Y. The mechanism of Axl-mediated Ebola virus infection. J. Infect. Dis.
2007, 196 (Suppl. 2), S259–S263. [CrossRef] [PubMed]
9. Takada, A.; Watanabe, S.; Ito, H.; Okazaki, K.; Kida, H.; Kawaoka, Y. Downregulation of beta1 integrins by
Ebola virus glycoprotein: implication for virus entry. Virology 2000, 278, 20–26. [CrossRef] [PubMed]
10. Long, J.; Wright, E.; Molesti, E.; Temperton, N.; Barclay, W. Antiviral therapies against Ebola and other
emerging viral diseases using existing medicines that block virus entry. F1000Research 2015, 4, 30. [CrossRef]
[PubMed]
11. Garcia, M.; Cooper, A.; Shi, W.; Bornmann, W.; Carrion, R.; Kalman, D.; Nabel, G.J. Productive replication
of Ebola virus is regulated by the c-Abl1 tyrosine kinase. Sci. Transl. Med. 2012, 4, 123ra24. [CrossRef]
[PubMed]
12. Uebelhoer, L.S.; Albarino, C.G.; McMullan, L.K.; Chakrabarti, A.K.; Vincent, J.P.; Nichol, S.T.; Towner, J.S.
High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola
viruses. Antivir. Res. 2014, 106, 86–94. [CrossRef] [PubMed]
13. Kouznetsova, J.; Sun, W.; Martinez-Romero, C.; Tawa, G.; Shinn, P.; Chen, C.Z.; Schimmer, A.; Sanderson, P.;
McKew, J.C.; Zheng, W.; et al. Identification of 53 compounds that block Ebola virus-like particle entry via a
repurposing screen of approved drugs. Emerg. Microbes Infect. 2014, 3, e84. [CrossRef] [PubMed]
14. Quillinan, N.P.; McIntosh, D.; Vernes, J.; Haq, S.; Denton, C.P. Treatment of diffuse systemic sclerosis with
hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial. Ann. Rheum. Dis.
2014, 73, 56–61. [CrossRef] [PubMed]
15. Ghosh, C.; Manjunath, G.B.; Akkapeddi, P.; Yarlagadda, V.; Hoque, J.; Uppu, D.S.; Konai, M.M.; Haldar, J.
Small molecular antibacterial peptoid mimics: the simpler the better! J. Med. Chem. 2014, 57, 1428–1436.
[CrossRef] [PubMed]
16. Ghosh, C.; Manjunath, G.B.; Konai, M.M.; Uppu, D.S.; Hoque, J.; Paramanandham, K.; Shome, B.R.; Haldar, J.
Aryl-Alkyl-Lysines: Agents That Kill Planktonic Cells, Persister Cells, Biofilms of MRSA and Protect Mice
from Skin-Infection. PLoS ONE 2015, 10, e0144094. [CrossRef] [PubMed]
17. Konai, M.M.; Haldar, J. Lysine-based small molecules that disrupt biofilms and kill both actively growing
planktonic and nondividing stationary phase bacteria. ACS Infect. Dis. 2015, 1, 469–478. [CrossRef] [PubMed]
18. Ghosh, C.; Manjunath, G.B.; Konai, M.M.; Uppu, D.S.; Hoque, J.; Paramanandham, K.; Shome, B.R.;
Ravikumar, R.; Haldar, J. Aryl-alkyl-lysines: Membrane-active small molecules active against murine
model of burn infection. ACS Infect. Dis. 2016, 2, 111–122. [CrossRef] [PubMed]
Viruses 2016, 8, 277 16 of 17
19. Konai, M.M.; Ghosh, C.; Yarlagadda, V.; Samaddar, S.; Haldar, J. Membrane active phenylalanine conjugated
lipophilic norspermidine derivatives with selective antibacterial activity. J. Med. Chem. 2014, 57, 9409–9423.
[CrossRef] [PubMed]
20. Konai, M.M.; Adhikary, U.; Samaddar, S.; Ghosh, C.; Haldar, J. Structure-Activity Relationship of Amino Acid
Tunable Lipidated Norspermidine Conjugates: Disrupting Biofilms with Potent Activity against Bacterial
Persisters. Bioconjugate Chem. 2015, 26, 2442–2453. [CrossRef] [PubMed]
21. Clinton, T.R.; Weinstock, M.T.; Jacobsen, M.T.; Szabo-Fresnais, N.; Pandya, M.J.; Whitby, F.G.; Herbert, A.S.;
Prugar, L.I.; McKinnon, R.; Hill, C.P.; et al. Design and characterization of ebolavirus GP prehairpin
intermediate mimics as drug targets. Protein Sci. 2015, 24, 446–463. [CrossRef] [PubMed]
22. Picazo, E.; Giordanetto, F. Small molecule inhibitors of ebola virus infection. Drug Discov. Today 2015, 20,
277–286. [CrossRef] [PubMed]
23. Selakovic, Z.; Soloveva, V.; Gharibeh, D.N.; Wells, J.; Segan, S.; Panchal, R.G.; Solaja, B.A. Anti-Ebola activity
of diazachrysene small molecules. ACS Infect. Dis. 2015, 1, 264–271. [CrossRef] [PubMed]
24. Chang, J.; Warren, T.K.; Zhao, X.; Gill, T.; Guo, F.; Wang, L.; Comunale, M.A.; Du, Y.; Alonzi, D.S.; Yu, W.; et al.
Small molecule inhibitors of ER alpha-glucosidases are active against multiple hemorrhagic fever viruses.
Antivir. Res. 2013, 98, 432–440. [CrossRef] [PubMed]
25. Sanchez, A. Analysis of filovirus entry into vero e6 cells, using inhibitors of endocytosis, endosomal
acidification, structural integrity, and cathepsin (B and L) activity. J. Infect. Dis. 2007, 196 (Suppl. 2),
S251–S258. [CrossRef] [PubMed]
26. Muller, S.; Moller, P.; Bick, M.J.; Wurr, S.; Becker, S.; Gunther, S.; Kummerer, B.M. Inhibition of filovirus
replication by the zinc finger antiviral protein. J. Virol. 2007, 81, 2391–2400. [CrossRef] [PubMed]
27. Takada, A.; Ebihara, H.; Jones, S.; Feldmann, H.; Kawaoka, Y. Protective efficacy of neutralizing antibodies
against Ebola virus infection. Vaccine 2007, 25, 993–999. [CrossRef] [PubMed]
28. Kuhn, J.H.; Lofts, L.L.; Kugelman, J.R.; Smither, S.J.; Lever, M.S.; van der Groen, G.; Johnson, K.M.;
Radoshitzky, S.R.; Bavari, S.; Jahrling, P.B.; et al. Reidentification of Ebola Virus E718 and ME as Ebola
Virus/H.sapiens-tc/COD/1976/Yambuku-Ecran. Genome Announc. 2014, 2. [CrossRef] [PubMed]
29. Trombley, A.R.; Wachter, L.; Garrison, J.; Buckley-Beason, V.A.; Jahrling, J.; Hensley, L.E.; Schoepp, R.J.;
Norwood, D.A.; Goba, A.; Fair, J.N.; et al. Comprehensive panel of real-time TaqMan polymerase chain
reaction assays for detection and absolute quantification of filoviruses, arenaviruses, and New World
hantaviruses. Am. J. Trop. Med. Hyg. 2010, 82, 954–960. [CrossRef] [PubMed]
30. Dowall, S.; Taylor, I.; Yeates, P.; Smith, L.; Rule, A.; Easterbrook, L.; Bruce, C.; Cook, N.; Corbin-Lickfett, K.;
Empig, C.; et al. Catheterized guinea pigs infected with Ebola Zaire virus allows safer sequential sampling
to determine the pharmacokinetic profile of a phosphatidylserine-targeting monoclonal antibody. Antivir.
Res. 2013, 97, 108–111. [CrossRef] [PubMed]
31. Dowall, S.D.; Matthews, D.A.; Garcia-Dorival, I.; Taylor, I.; Kenny, J.; Hertz-Fowler, C.; Hall, N.;
Corbin-Lickfett, K.; Empig, C.; Schlunegger, K.; et al. Elucidating variations in the nucleotide sequence of
Ebola virus associated with increasing pathogenicity. Genome Biol. 2014, 15, 540. [CrossRef] [PubMed]
32. Assistant Secretary of Defense for Research and Engineering. Technology Readiness Assessment (TRA)
Guidance. Department of Defense, April 2011.
33. Gunther, S.; Asper, M.; Roser, C.; Luna, L.K.; Drosten, C.; Becker-Ziaja, B.; Borowski, P.; Chen, H.M.;
Hosmane, R.S. Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS
coronavirus and Ebola virus in vitro. Antivir. Res. 2004, 63, 209–215. [CrossRef] [PubMed]
34. McCarthy, S.D.; Majchrzak-Kita, B.; Racine, T.; Kozlowski, H.N.; Baker, D.P.; Hoenen, T.; Kobinger, G.P.;
Fish, E.N.; Branch, D.R. A Rapid Screening Assay Identifies Monotherapy with Interferon-ss and
Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus. PLoS Negl. Trop. Dis.
2016, 10, e0004364. [CrossRef] [PubMed]
35. Johansen, L.M.; Brannan, J.M.; Delos, S.E.; Shoemaker, C.J.; Stossel, A.; Lear, C.; Hoffstrom, B.G.; Dewald, L.E.;
Schornberg, K.L.; Scully, C.; et al. FDA-approved selective estrogen receptor modulators inhibit Ebola virus
infection. Sci. Transl. Med. 2013, 5, 190ra79. [CrossRef] [PubMed]
36. Lind, T.; Rydberg, L.; Kyleback, A.; Jonsson, A.; Andersson, T.; Hasselgren, G.; Holmberg, J.;
Rohss, K. Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of
gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 2000, 14, 861–867. [CrossRef] [PubMed]
Viruses 2016, 8, 277 17 of 17
37. Speed, B.; Bu, H.Z.; Pool, W.F.; Peng, G.W.; Wu, E.Y.; Patyna, S.; Bello, C.; Kang, P. Pharmacokinetics,
distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. Drug Metab. Dispos. 2012, 40,
539–555. [CrossRef] [PubMed]
38. Gronchi, A.; Blay, J.Y.; Trent, J.C. The role of high-dose imatinib in the management of patients with
gastrointestinal stromal tumor. Cancer 2010, 116, 1847–1858. [CrossRef] [PubMed]
39. Cross, R.W.; Fenton, K.A.; Geisbert, J.B.; Mire, C.E.; Geisbert, T.W. Modeling the Disease Course of Zaire
ebolavirus Infection in the Outbred Guinea Pig. J. Infect. Dis. 2015, 212, S305–S315. [CrossRef] [PubMed]
40. Fleuren, E.D.; Hillebrandt-Roeffen, M.H.; Flucke, U.E.; Te Loo, D.M.; Boerman, O.C.; van der Graaf, W.T.;
Versleijen-Jonkers, Y.M. The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor
BGB324 in Ewing sarcoma. Oncotarget 2014, 5, 12753–12768. [CrossRef] [PubMed]
41. Uppu, D.S.; Akkapeddi, P.; Manjunath, G.B.; Yarlagadda, V.; Hoque, J.; Haldar, J. Polymers with tunable
side-chain amphiphilicity as non-hemolytic antibacterial agents. Chem. Commun. (Camb.) 2013, 49, 9389–9391.
[CrossRef] [PubMed]
42. Egorin, M.J.; Lagattuta, T.F.; Hamburger, D.R.; Covey, J.M.; White, K.D.; Musser, S.M.;
Eiseman, J.L. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-
17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother. Pharmacol.
2002, 49, 7–19. [CrossRef] [PubMed]
43. Bente, D.; Gren, J.; Strong, J.E.; Feldmann, H. Disease modeling for Ebola and Marburg viruses.
Dis. Models Mech. 2009, 2, 12–17. [CrossRef] [PubMed]
44. Li, D.; Chen, T.; Hu, Y.; Zhou, Y.; Liu, Q.; Zhou, D.; Jin, X.; Huang, Z. An Ebola virus-like particle-based
reporter system enables evaluation of antiviral drugs in vivo under non-BSL-4 conditions. J. Virol. 2016, 90,
8720–8728. [CrossRef] [PubMed]
45. Edwards, M.R.; Pietzsch, C.; Vausselin, T.; Shaw, M.L.; Bukreyev, A.; Basler, C.F. High-Throughput
Minigenome System for Identifying Small-Molecule Inhibitors of Ebola Virus Replication. ACS Infect. Dis.
2015, 1, 380–387. [CrossRef] [PubMed]
46. Director, Research Directorate (DRD). Technology Readiness Assessment (TRA) Deskbook. Department of
Defense, July 2009.
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
